Literature DB >> 2873075

Sulfapyridine appearance in plasma after salicylazosulfapyridine. Another simple measure of intestinal transit.

J E Kellow, T J Borody, S F Phillips, A C Haddad, M L Brown.   

Abstract

The appearance of sulfapyridine in plasma after oral administration of salicylazosulfapyridine (SASP) was evaluated as a method for defining arrival time in the cecum, an index of small bowel transit. After direct instillation of SASP and lactulose into the cecum, the appearances of their metabolites (sulfapyridine in plasma and hydrogen in breath) were rapid (1-10 min) and simultaneous. When a mixture of SASP and lactulose was taken by mouth, times of the respective "signals" varied among individuals from 40 to 180 min (n = 8) but were correlated within individuals. Salicylazosulfapyridine transit times from duodenum to cecum were also very similar to simultaneous measurements of transit by scintigraphic monitoring of technetium 99m. Timing of the sulfapyridine signal corresponded to the arrival of 5%-13% of technetium 99m DTPA in the cecum. Exemplifying the use of this new technique, simultaneous administration of lactulose into the stomach and SASP into the duodenum yielded consistently longer stomach-to-cecum than duodenum-to-cecum transits, attributable to the delay caused by gastric emptying. Therapeutic doses of morphine delayed small bowel transit of SASP. Transit of SASP offers a second marker technique for the cecal arrival of the "head" of a bolus; the approach may be useful as an inexpensive, noninvasive measurement of transit.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873075     DOI: 10.1016/0016-5085(86)90574-3

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  14 in total

1.  Cigarette smoking and nicotine delay postprandial mouth-cecum transit time.

Authors:  A M Scott; J E Kellow; G M Eckersley; J M Nolan; M P Jones
Journal:  Dig Dis Sci       Date:  1992-10       Impact factor: 3.199

2.  A gastrointestinal transit study on amphotericin B-loaded solid lipid nanoparticles in rats.

Authors:  Hilda Amekyeh; Nashiru Billa; Kah-Hay Yuen; Sherlyn Lim Sheau Chin
Journal:  AAPS PharmSciTech       Date:  2015-01-15       Impact factor: 3.246

3.  Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea.

Authors:  D Sharpstone; P Neild; R Crane; C Taylor; C Hodgson; R Sherwood; B Gazzard; I Bjarnason
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

4.  Effects of a non-absorbable osmotic load on drug absorption in healthy volunteers.

Authors:  S A Riley; M Kim; F Sutcliffe; M Kapas; M Rowland; L A Turnberg
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

5.  Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease.

Authors:  K Teahon; S Somasundaram; T Smith; I Menzies; I Bjarnason
Journal:  Gut       Date:  1996-06       Impact factor: 23.059

6.  Fructose-sorbitol ingestion provokes gastrointestinal symptoms in patients with eating disorders.

Authors:  Noel Friesen; Ross D Hansen; Suzanne F Abraham; John E Kellow
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

7.  Sulfamethizole capsule method. A new method for assessing gastric emptying of solids.

Authors:  T Asada; M Murakami; Y Sako; Y Fukushima; Y Yonekura; J Konishi; T Kita; T Miyake; T Asada
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

8.  Simultaneous noninvasive evaluation of gastric emptying and orocaecal transit times. Use in studying the actions of cisapride in diabetic patients.

Authors:  J F Bergmann; O Chassany; P J Guillausseau; M Bayle; S Chagnon; C Caulin; J R Sallenave
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Breath hydrogen response to lactulose in healthy subjects: relationship to methane producing status.

Authors:  D Cloarec; F Bornet; S Gouilloud; J L Barry; B Salim; J P Galmiche
Journal:  Gut       Date:  1990-03       Impact factor: 23.059

10.  Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides.

Authors:  N J Talley; S F Phillips; A Haddad; L J Miller; C Twomey; A R Zinsmeister; A Ciociola
Journal:  Dig Dis Sci       Date:  1989-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.